Mutations in the IFNγ receptor IFNGR1 [76], signaling adaptors JAK1 and JAK2 [63,65,77,78] or components of the IFNγ signaling cascade, such as STAT1 and IRF1 [79,80] were associated with cancer progression and immunotherapy resistance. This evidence concerns the gene IFNG and cancer.